MRM

MEDIROM Healthcare Technologies Inc. (MRM) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.8/10 — Weak · Last Updated: 2026-09-01

Overall Score

Growth

Revenue base is modest relative to enterprise value, with EV/Sales at 0.81x.

Operating performance remains negative, with EBIT margin at -19.8% and EBITDA margin at -12.9%.

Cash conversion is weak, with operating cash flow margin at -9.1% and free cash flow margin at -16.1%.

Profitability

Return metrics remain deeply negative, including ROE at -68.4% and ROIC at -19.3%.

Gross margin is only 25.3%, while operating margin is -19.8%.

Interest coverage is negative at -8.7x, reflecting ongoing earnings pressure.

Financial Health

Liquidity is acceptable with a current ratio of 1.75x and quick ratio of 1.75x.

Leverage remains elevated, with debt-to-equity at 1.75x and debt-to-assets at 56.1%.

Cash balance is thin relative to obligations, with cash per share at 2.55 and a cash ratio of 0.01x.

Valuation

The stock screens cheap on sales at 0.20x P/S and 0.85x P/B.

However, negative earnings and cash flow make P/E and cash flow multiples less meaningful.

Enterprise value remains high relative to cash generation, with EV/FCF at -8.5x and EV/OCF at -8.9x.

Momentum

No recent news was provided to indicate a positive catalyst.

The framework currently lacks evidence of improving operating momentum.

Absent fresh catalysts, the setup remains weak for a 10-year growth case.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on MEDIROM Healthcare Technologies Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →